PARP1 and neoplasm: Mir-182 overexpressing tumor cells were hypersensitive to inhibitors of poly (ADP-ribose) polymerase 1 (PARP1); on the contrary, miR-182 antagonism led to enhanced BRCA-1 levels and induced resistance to PARP1 inhibitors.